Insights

Innovative Stem Cell Therapies Xintela specializes in developing targeted stem cell and cancer therapies based on proprietary integrin markers, providing potential opportunities to collaborate or supply advanced biomaterials and cell products for clinical research and therapeutic applications.

Clinical Development Stage With products like XSTEM in clinical trials for osteoarthritis and ulcers, there is a need for specialized GMP manufacturing solutions, quality assurance tools, and patient-specific cell processing technologies to support their ongoing clinical programs.

Expanding Leadership The recent appointment of a Chief Scientific Officer highlights growth in scientific expertise, opening avenues for partnerships in research collaborations, joint ventures, and technology licensing to accelerate product development.

Strategic Partnerships Recent collaborations with financial advisory firms like Carnegie Investment Bank and notable board appointments suggest an openness to investment and strategic alliances, presenting opportunities for business development and funding support.

Market Focus and Potential Targeting high-impact areas such as triple-negative breast cancer and glioblastoma, Xintela presents opportunities to introduce diagnostic and therapeutic solutions, including antibody development, in niche oncology markets with unmet needs.

Xintela AB Email Formats	Example	Percentage
First.Last@xintela.se	John.Doe@xintela.se	37%
First@xintela.se	John@xintela.se	19%
Last@xintela.se	Doe@xintela.se	7%
First.Last@xintela.se	John.Doe@xintela.se	37%

Xintela AB Email Formats

Example

Percentage

First.Last@xintela.se

John.Doe@xintela.se

37%

First@xintela.se

John@xintela.se

19%

Last@xintela.se

Doe@xintela.se

First.Last@xintela.se

John.Doe@xintela.se

37%

Frequently Asked Questions

Where is Xintela AB's headquarters located?

Xintela AB's main headquarters is located at Scheelevägen, Lund, Skåne 22381, SE. The company has employees across 1 continents, including Europe.

What is Xintela AB's phone number?

You can contact Xintela AB's main corporate office by phone at

+46-70-329-1****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Xintela AB's official website and social media links?

Xintela AB's official website is xintela.se and has social profiles on LinkedIn Crunchbase.

What is Xintela AB's SIC code NAICS code?

Xintela AB's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Xintela AB have currently?

As of October 2025, Xintela AB has approximately 19 employees across 1 continents, including Europe. Key team members include Chief Scientific Officer: L. V.Head Of Quality Control: K. S.Head Of Manufacturing: C. R.. Explore Xintela AB's employee directory with LeadIQ.

What industry does Xintela AB belong to?

Xintela AB operates in the Biotechnology Research industry.

What technology does Xintela AB use?

Xintela AB's tech stack includes jQueryAdobe Fonts.

What is Xintela AB's email format?

Xintela AB's email format typically follows the pattern of First.Last@xintela.se. Find more Xintela AB email formats with LeadIQ.

When was Xintela AB founded?

Xintela AB was founded in 2009.

Xintela AB

Biotechnology ResearchSweden11-50 Employees

Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin α10β1 (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma.

Insights

Similar companies to Xintela AB

Rubius Therapeutics

Vertex Pharmaceuticals

Cellectis

Editas Medicine

bluebird bio

CRISPR Therapeutics

Xintela AB Tech Stack

Media & News

Xintela AB hires Lucienne Vonk as Chief Scientific Officer.

Xintela AB partners with Carnegie Investment Bank AB.

Xintela AB hired Lars Hedbys as Board of Directors on Nov 12th '20.

Xintela AB launches PCT) patent application for quality-assured chondrocytes.

Xintela AB's Email Address Formats